ClinicalTrials.gg
Enrolling by invitationNCT07062757Updated Jul 14, 2025

Lymphatic Drainage Massage and Melatonin in Post-Orthognathic Surgery Pain and Edema

An interventional study of no intervention and lymphatic drainage massage in Dentofacial Deformities, Edema and Pain, sponsored by Bezmialem Vakif University. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to participants aged 16 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Bezmialem Vakif University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2025, registered Jun 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
16 Years to 55 Years
Sex
All
01

Study summary

Lymphatic drainage massage is one of the most essential techniques for reducing edema. It is a very gentle, monotonous, slow, rhythmic massage applied to the skin's surface. This technique accelerates the flow of lymphatic fluid, minimizing swelling and providing relief. Frequently used after orthognathic surgery, lymphatic drainage massage helps reduce edema, enhancing patients' postoperative comfort.

Read the detailed description

Melatonin, a hormone produced by the pineal gland, is a neurochemical substance that functions in harmony with the body's natural rhythm. In addition to its presence in the brain, melatonin can also be found in the retina, bone marrow, intestines, skin, and various blood cells. Conditions such as insomnia or jet lag may benefit from melatonin supplements. Beyond its role in improving sleep quality, melatonin also contributes to regulating the immune system, body temperature, blood pressure, and cortisol hormone levels.

Another important function of melatonin is its powerful free radical-scavenging ability. It can neutralize both reactive oxygen species and reactive nitrogen species. Due to its strong antioxidant properties, several studies have investigated its effects on pain and edema. Research has shown that preoperative and postoperative melatonin administration can reduce postoperative pain and accelerate sensory recovery through its antioxidant effects.

02

Conditions studied

  • Dentofacial Deformities
  • Edema
  • Pain

Keywords

  • dentafacial deformities
  • edema
  • pain
03

In context

Dentofacial Deformities

40 studies on the registry are indexed under Dentofacial Deformities; 16 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 25 interventional studies indexed under Dentofacial Deformities.

Browse Dentofacial Deformities studies →

Lead sponsor

Bezmialem Vakif University is the lead sponsor of 354 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with dentofacial deformities who are planned to undergo orthognathic surgery
  2. Patients who have not previously undergone orthognathic surgery
  3. Patients with no systemic diseases

Exclusion criteria

Exclusion Criteria:

  1. Presence of systemic diseases affecting general health
  2. Presence of malignant disease in the head and neck region
  3. Patients who have previously undergone orthognathic surgery
  4. Patients with any bleeding disorders
  5. Patients with cardiovascular disease who are under anticoagulant or antiplatelet therapy
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Sham comparator
    group 1 (No intervention)

    No intervention will be applied to prevent edema in this group of patients.

    Other: no intervention

  • Experimental
    group 2 (lymphatic drainage massage)

    In this group of patients, a total of 10 sessions of lymphatic drainage massage will be applied, starting from the 2nd postoperative day, with 2 sessions per week

    Other: lymphatic drainage massage

  • Experimental
    group 3 (oral melatonin tablet)

    In this group of patients, the first dose of 10 mg oral melatonin tablet will be administered one day before the operation, and the patients will take the tablet daily for a total of 21 days.

    Dietary Supplement: oral melatonin tablet

  • Experimental
    group 4 (both melatonin and lymphatic drainage)

    In this group of patients, both melatonin and lymphatic drainage procedures will be applied together.

    Other: lymphatic drainage massage · Dietary Supplement: oral melatonin tablet · Combination Product: both melatonin and lymphatic drainage

Interventions

  • Otherno intervention

    this group patients receive any medication for edema control.

  • Otherlymphatic drainage massage

    A total of 10 sessions of lymphatic drainage massage will be applied to this group of patients, starting from the 2nd postoperative day, with 2 sessions per week.

  • Dietary supplementoral melatonin tablet

    In this group of patients, the first dose of 10 mg oral melatonin tablet will be given one day prior to the operation, and the patients will continue taking the tablet daily for a total of 21 days.

  • Combination productboth melatonin and lymphatic drainage

    In this group of patients, a total of 10 sessions of lymphatic drainage massage will be applied starting from the 2nd postoperative day, with 2 sessions per week, while the first dose of 10 mg oral melatonin tablet will be administered one day prior to the operation, and the patients will continue taking the tablet daily for 21 days.

06

What researchers measure

Primary outcomes

  1. Postoperative edema assessment

    Postoperative edema measurements will be taken after the patient is anesthetized before surgery and on the 1st, 3rd, and 7th postoperative days. Before the surgery, the gonion and tragus will be marked with methylene blue, and the distance between the gonion-lateral canthus and tragus-labial commissure will be measured and recorded using a thread. Measurements will be repeated on postoperative days 1, 3, 7, 14, 21, and 28 and recorded in the evaluation form.

    Time frame: 1month

Secondary outcomes

  1. pain assessment

    VAS assessment will be performed on all days when edema measurements are taken for pain evaluation.

    Time frame: 1 month

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 14, 2025
StartActual
Mar 30, 2025
Primary completionEst.
Mar 30, 2027
CompletionEst.
May 30, 2027
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07062757
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Mar 30, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Jul 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion